Close Menu

multiple myeloma

"It may be possible to use available drugs on the shelf that are effective in melanoma to treat myeloma patients with similar mutations," said Kenneth Anderson, the program director and chief of hematologic neoplasias at the Dana-Farber Cancer Institute, adding that he envisions a "very rapid bench-to-bedside translation."

Based on their whole-genome or exome analyses of multiple myeloma samples from 38 individuals, members of the Multiple Myeloma Research Consortium have learned more about known pathways contributing to the disease and identified several previously unidentified genetic players.

Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US.

Signal will use its genomic testing platform in a multiple myeloma research program being conducted by Array BioPharma.

The company will use part of the €1 million award to investigate biomarkers that will aid in determining which patients are the best candidates for treatment with its MOR202 antibody program, a company official said.

The company said that the protein's expression profile indicates that it might also be useful as a diagnostic and prognostic marker for multiple myeloma.

The results represent the first findings for the MMRC Genomics Initiative, which kicked off last year and aims to initially sequence 50 tumors from patients, and then sequence relevant targets in 200 more samples.

Researchers involved in the Multiple Myeloma Research Consortium Genomics Initiative reported on their initial sequence and copy number analyses of multiple myeloma genomes at the American Association for Cancer Research annual meeting this week.

The initiative, which involves the Broad Institute and the Translational Genomics Research Institute, aims to comprehensively analyze the genomes of 250 multiple myeloma samples. MMRF said this spring that as part of the project, the Broad would sequence the genomes of at least 50 of the tumors.

The firm will use the undisclosed amount to optimize the protocols for its genomic-selection application and to start building a sales and marketing force that "will become more visible in the second half of this year," CEO Fred Dom said.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.